Advertisement

Topics

Exon-Intron, Inc. Company Profile

17:55 EST 15th December 2018 | BioPortfolio

Exon-Intron, Inc. is a biotechnology education firm. This year we celebrate our 18th anniversary and the continuation of our long tradition as a provider of expert technical training to scientists of virtually every level of sophistication. By placing great emphasis on hands-on, laboratory-intensive training, our workshops provide the researcher with the necessary skills and insight to plan and perform cutting-edge research, and to interpret the resulting data. These programs are comprehensive and provide the participant with enough knowledge to be conversant in the language of biotechnology and to teach these methods to students in all areas of science.

Location

P.O. Box 395
Loganville
Pennsylvania
17342
United States of America

Contact

Phone: 717-428-3780
Fax: 717-771-4062
Email: workshop@DNAtech.com


News Articles [40 Associated News Articles listed on BioPortfolio]

Roivant Licenses iNtRON Bio's Anti-Bacterial in $667.5 Million Deal

Under the terms of the deal, Roivant is paying iNtRON Bio $10 million upfront. iNtRON will be eligible for milestone payments. When the first patient receives treatment in a U.S. Phase II clinical tri...

Roivant and iNtRON sign licensing deal for SAL200

Roivant Sciences and iNtRON Biotechnology have signed a $667.5m global licensing agreement for SAL200, which is an investigational biologic to...Read More... The post Roivant and iNtRON sign licensing...

Scientists Wipe Out a Mosquito Population Through Genome-editing

Scientist Andrea Crisanti from Imperial College London in the United Kingdom and colleagues edit the doublesex gene in the mosquito malaria vector Anopheles gambiae using CRISPR-Cas9. Through the disr...

Roivant gets rights to iNtRON's SAL200

Roivant Sciences GMBH licensed worldwide rights to iNtRON Biotechnology Inc.’s infectious disease compound SAL200.

Roivant, iNtRON Bio ink licensing deal for novel anti─superbugs biologic SAL200

Roivant Sciences and iNtRON Biotechnology have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of infectious diseases caused by antibiotic─re...

FDA Approves Dacomitinib for Frontline EGFR+ NSCLC

The FDA has approved dacomitinib (Vizimpro) for the frontline treatment of patients with metastatic non–small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutat...

Roivant Buoys Anti-Infective Portfolio With Novel iNtRON Asset

Roivant Sciences has added iNtRON Biotechnology’s novel biologic candidate to its existing anti-infective portfolio in a sizable licensing deal amid...   

Deals this week: Roivant Sciences, Inflazome, Santhera

Roivant Sciences will use biologic drug candidate SAL200 are entering a global licensing agreement worth $667.5m with iNtRON Biotechnology. iNtRON...Read More... The post Deals this week: Roivant Scie...

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Ribavirin [Aurobindo Pharma Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin capsules. Ribavirin Capsules Initial U.S. Approval: ...

Ribavirin [Cadila Healthcare Limited]

These highlights do not include all the information needed to use ribavirin capsules safely and effectively. See full prescribing information for ribavirin capsules. Initial U.S. Approval: 1998

Ribavirin [Zydus Pharmaceuticals (USA) Inc.]

These highlights do not include all the information needed to use ribavirin capsules safely and effectively. See full prescribing information for ribavirin capsules. Initial U.S. Approval: 1998

Ribavirin [Sandoz Inc]

These highlights do not include all the information needed to use Ribavirin safely and effectively. See full prescribing information for Ribavirin.Ribavirin Capsules Initial U.S. Approval: 1998

Ribavirin [American Health Packaging]

These highlights do not include all the information needed to use Ribavirin safely and effectively. See full prescribing information for Ribavirin.Ribavirin Capsules Initial U.S. Approval: 1998

PubMed Articles [268 Associated PubMed Articles listed on BioPortfolio]

A highly proliferative group IIC intron from Geobacillus stearothermophilus reveals new features of group II intron mobility and splicing.

The thermostable Geobacillus stearothermophilus GsI-IIC intron is among the few bacterial group II introns found to proliferate to high copy number in its host genome. Here, we developed a bacterial g...

Structural accommodations accompanying splicing of a group II intron RNP.

Group II introns, the putative progenitors of spliceosomal introns and retrotransposons, are ribozymes that are capable of self-splicing and DNA invasion. In the cell, group II introns form ribonucleo...

Genome-wide identification, phylogenetic classification, and exon-intron structure characterisation of the tubulin and actin genes in flax (Linum usitatissimum).

Flax (Linum usitatissimum L.) is a valuable food and fiber crop cultivated for its quality fiber and seed oil. α-, β-, γ-tubulins and actins are the main structural proteins of the cytoskeleton. α...

Identification of a variant-associated with early-onset diabetes in the intron of INS gene with exome sequencing.

Whole-exome sequencing is a new technology. We used it to explore the gene responsible for early-onset diabetes due to impaired insulin secretion in a family. In the INS gene, we identified the hetero...

Evolution, expression, and characterisation of liver-expressed antimicrobial peptide genes in ancient chondrostean sturgeons.

Liver-expressed antimicrobial peptide 2 (leap-2) is an evolutionarily ancient molecule that acts as the key component in vertebrate innate immunity against invading pathogens. Leap-2 has been identifi...

Clinical Trials [124 Associated Clinical Trials listed on BioPortfolio]

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma (MK-4031-002)

This is a Phase II/III randomized, controlled, multicenter, open-label study designed to assess the safety, efficacy, and impact on quality of life of PEG Intron and INTRON® A and the pop...

Phase III PEG-Intron in HIV-infected Patients (Study P00738)

This is a randomized, double-blind, multicenter trial testing 2 doses of PEG-Intron, 1.0mcg/kg/week and 3.0mcg/kg/week in heavily treatment-experienced HIV-infected patients compared to pl...

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

The purpose of this study is to see if PEG-Intron is safe and tolerated when given to children, to see how much gets into the blood and how long it stays in the blood, and to see how well ...

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

This is an open-label, single-arm, multicenter Phase II safety and efficacy study of combination therapy with pembrolizumab and PEG-Intron (Peginterferon alpha-2b) in patients with advance...

Peg-Intron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (Study P04498)(COMPLETED)

This is an open label, randomized, comparative, multi-center study. Subjects will be screened within 2 weeks prior to study entry to establish eligibility. Subjects who meet all the sele...

Companies [8 Associated Companies listed on BioPortfolio]

Exon-Intron, Inc.

Exon-Intron, Inc. is a biotechnology education firm. This year we celebrate our 18th anniversary and the continuation of our long tradition as a provider of expert technical training to scientists of ...

INTRON BIO TECHNOLOGY

NIL

Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of prot...

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of prot...

Prosensa

Prosensa is an innovative Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics correcting gene expression in ...

More Information about "Exon-Intron, Inc." on BioPortfolio

We have published hundreds of Exon-Intron, Inc. news stories on BioPortfolio along with dozens of Exon-Intron, Inc. Clinical Trials and PubMed Articles about Exon-Intron, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Exon-Intron, Inc. Companies in our database. You can also find out about relevant Exon-Intron, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record